AI
Saturday, March 04, 2017 11:03:24 AM
Mem.Sloan/Wolchok, Biomarkers, NCCN/AZN Trials – tightly related imo...
CHRONOLOGICALLY:
5-29-15: Peregrine & Sloan Kettering Enter Collab. to “Investigate Novel PS-Targeting Immunotherapy Combos” http://tinyurl.com/o3k9ux8
JEDD WOLCHOK: ”The phosphatidylserine (PS) signaling pathway is a very interesting target for modulating the immune system's response to cancer. We look forward to exploring the potential of PS-targeting agents alone and with other immune modulators that may lead to novel advances in cancer therapy."
8-24-15: Peregrine & AstraZeneca & Peregrine Enter Collab. to run Ph1/Bavi+Durva/mult. solid tumors http://tinyurl.com/owlxpsf
...and then: 10-15-15: Peregrine & AstraZeneca Expand Collab. to run Ph2/Bavi+Durva/2L_NSCLS http://tinyurl.com/q79bkam
1-6-16: Peregrine enters into Research Collab. with NCCN http://tinyurl.com/zmxtpsb
1-11-16: Peregrine Plans Expansion of Bavi Clinical Pgm http://tinyurl.com/zhdy37a
...New Ph2/Bavi+Chemo/TNBC, which “originated from Peregrine's ongoing collab. W/MSKCC”. One site will be Providence CC/Portland w/P.I.=David Page.
Note1: ProvidenceCC was a SUNRISE site w/P.I.=Rachel Sanborn(Dir./Thoracic-Onology, Providence CC).
Note2: David Page worked & published w/J.Wolchok at MSKCC – ex: http://www.hemonc.theclinics.com/article/S0889-8588(14)00017-3/abstract
9-6-16: NCCN Awards 3 Bavi Trials, to begin "Early 2017" http://tinyurl.com/gutgwb5
...1: Ph1/Hepatocellular Cancer (Bavi+RAD+Sorafenib), MOFFITT CANCER CENTER, PI: Jessica Frakes, MD (Clinicaltrials has start=4-30-17)
...2: P1-2/Glioblastoma (Bavi+RAD+Merck’s Temodar), MASS-GEN. CC, PI: Elizabeth Gerstner, MD
...3: Ph2/Head+Neck (Bavi+Merck’s Keytruda), JOHN-HOPKINS(Sidney Kimmel CC), PI: Ranee Mehra, MD
10-10-16/ESMO’16: Sunrise Biomarker #1 (B2GPI) announced http://tinyurl.com/hp73njt
...”We are optimistic that addl. Biomarkers associated with improved outcomes for bavituximab-containing treatments will be identified as the analysis continues.”
12-7-16/IASLC’16/Vienna: Sunrise Biomarker #2 (Complement Act. & IL-10) revealed in abstracts, but withdrawn due to “data anal. not complete”(IR) http://tinyurl.com/z8cq8vx
...LEAD AUTHOR: David E. Gerber/UTSW, SENIOR AUTHOR: Rachael Sanborn/ProvidenceCC
12-12-17/CC/S.King: “We are currently evaluating addl. Biomarkers that we hope will allow us to identify a profile for patients who will receive therapeutic benefits from a bavituximab-containing treatment regimen.” http://tinyurl.com/hhn4gga
3-1-17/AACR’17: Sunrise Biomarker #3 (INF-y) revealed in abstracts http://tinyurl.com/zdsbds8
...LEAD AUTHOR: N.Kallinteris (PPHM), SENIOR AUTHOR: Rachael Sanborn/ProvidenceCC
= = = =MY OPINIONS:
1. In think the newly revealed 4-3-17 AACR’17 Biomarker #3 (IFN-y) supplants the previous two. I think they kept searching for better & better ones, and #3 is the latest & greatest. Thus, it’s THE ONE they chose to show off at AACR’17.
2. I think that Jedd Wolchok and his Lab are deeply involved with helping PPHM put together the final protocol’s for the 3 NCCN trials and the planned AZN “Mult. Tumor Types” trial. You see Providence CC’s Dr. Rachael Sanborn appear as Senior Author of the last 2 Biomarker Abstracts, with ties back to MSKCC/Wolchok thru Providence Co-Oncologist David Page, who prev. worked with Dr. Jedd at Mem.Sloan. PPHM+MSK+PROVIDENCE, tightly working together on future Bavi Trials.
3. No better evidence as to how close PPHM & Mem.Sloan/Wolchok have become than to look at AACR’17 (See http://tinyurl.com/zzldh9n ). The new (2nd) PPHM+MSK study revealed by the 3-1-17 abstracts is a complete mindblower (to me!):
#2. MSKCC+PPHM: 4-3-17 #1651, “PSTargeting+Adoptive TCell Transfer (ACT) Eliminates Adv. Tumors w/o Off-Target Toxicities, Melanoma” <=NEW(2nd) Joint MemSloan/PPHM study, see: http://tinyurl.com/h3ylrku
.
.
= = = = = = = = = = = = = = = = = = = =
Dr. Wolchok spoke about Bavi in the 11-14-16/PR (SITC’16, Joint MSKCC & PPHM Poster, “Phosphatidylserine Targeting Antibody in Combination with Checkpoint Blockade & Tumor Radiation Therapy Promotes Anti-Cancer Activity in Mouse Melanoma”)…
FULL SITC’16 ABSTRACT #199: http://bit.ly/2dHTEVn
11-14-16/JEDD WOLCHOK: "Based on these study results, we believe that the targeting of PS is having meaningful activity within the tumor microenvironment in the B16 melanoma model. It appears that this activity creates a more immune active environment in which other treatments, including radiation, are able to have a greater anti-tumor impact." http://tinyurl.com/js3fca4
11-14-16/TAHA MERGHOUB (Co-Dir., MSK’s Ludwig Collab. Lab): "We have noted that the combination of PS-targeting treatment and radiation, as well as triple combination of PS-targeting treatment, radiation and anti-PD-1, resulted in clear advantages in anti-tumor activity in the mouse B16 melanoma model. We believe that these findings suggest the potential benefit of combining these agents to improve the outcomes of patients with cancer. With this in mind, we think this research may play an important role in designing future clinical trials of PS-targeting agents in melanoma and other cancers." http://tinyurl.com/js3fca4
CHRONOLOGICALLY:
5-29-15: Peregrine & Sloan Kettering Enter Collab. to “Investigate Novel PS-Targeting Immunotherapy Combos” http://tinyurl.com/o3k9ux8
JEDD WOLCHOK: ”The phosphatidylserine (PS) signaling pathway is a very interesting target for modulating the immune system's response to cancer. We look forward to exploring the potential of PS-targeting agents alone and with other immune modulators that may lead to novel advances in cancer therapy."
8-24-15: Peregrine & AstraZeneca & Peregrine Enter Collab. to run Ph1/Bavi+Durva/mult. solid tumors http://tinyurl.com/owlxpsf
...and then: 10-15-15: Peregrine & AstraZeneca Expand Collab. to run Ph2/Bavi+Durva/2L_NSCLS http://tinyurl.com/q79bkam
1-6-16: Peregrine enters into Research Collab. with NCCN http://tinyurl.com/zmxtpsb
1-11-16: Peregrine Plans Expansion of Bavi Clinical Pgm http://tinyurl.com/zhdy37a
...New Ph2/Bavi+Chemo/TNBC, which “originated from Peregrine's ongoing collab. W/MSKCC”. One site will be Providence CC/Portland w/P.I.=David Page.
Note1: ProvidenceCC was a SUNRISE site w/P.I.=Rachel Sanborn(Dir./Thoracic-Onology, Providence CC).
Note2: David Page worked & published w/J.Wolchok at MSKCC – ex: http://www.hemonc.theclinics.com/article/S0889-8588(14)00017-3/abstract
9-6-16: NCCN Awards 3 Bavi Trials, to begin "Early 2017" http://tinyurl.com/gutgwb5
...1: Ph1/Hepatocellular Cancer (Bavi+RAD+Sorafenib), MOFFITT CANCER CENTER, PI: Jessica Frakes, MD (Clinicaltrials has start=4-30-17)
...2: P1-2/Glioblastoma (Bavi+RAD+Merck’s Temodar), MASS-GEN. CC, PI: Elizabeth Gerstner, MD
...3: Ph2/Head+Neck (Bavi+Merck’s Keytruda), JOHN-HOPKINS(Sidney Kimmel CC), PI: Ranee Mehra, MD
10-10-16/ESMO’16: Sunrise Biomarker #1 (B2GPI) announced http://tinyurl.com/hp73njt
...”We are optimistic that addl. Biomarkers associated with improved outcomes for bavituximab-containing treatments will be identified as the analysis continues.”
12-7-16/IASLC’16/Vienna: Sunrise Biomarker #2 (Complement Act. & IL-10) revealed in abstracts, but withdrawn due to “data anal. not complete”(IR) http://tinyurl.com/z8cq8vx
...LEAD AUTHOR: David E. Gerber/UTSW, SENIOR AUTHOR: Rachael Sanborn/ProvidenceCC
12-12-17/CC/S.King: “We are currently evaluating addl. Biomarkers that we hope will allow us to identify a profile for patients who will receive therapeutic benefits from a bavituximab-containing treatment regimen.” http://tinyurl.com/hhn4gga
3-1-17/AACR’17: Sunrise Biomarker #3 (INF-y) revealed in abstracts http://tinyurl.com/zdsbds8
...LEAD AUTHOR: N.Kallinteris (PPHM), SENIOR AUTHOR: Rachael Sanborn/ProvidenceCC
= = = =MY OPINIONS:
1. In think the newly revealed 4-3-17 AACR’17 Biomarker #3 (IFN-y) supplants the previous two. I think they kept searching for better & better ones, and #3 is the latest & greatest. Thus, it’s THE ONE they chose to show off at AACR’17.
2. I think that Jedd Wolchok and his Lab are deeply involved with helping PPHM put together the final protocol’s for the 3 NCCN trials and the planned AZN “Mult. Tumor Types” trial. You see Providence CC’s Dr. Rachael Sanborn appear as Senior Author of the last 2 Biomarker Abstracts, with ties back to MSKCC/Wolchok thru Providence Co-Oncologist David Page, who prev. worked with Dr. Jedd at Mem.Sloan. PPHM+MSK+PROVIDENCE, tightly working together on future Bavi Trials.
3. No better evidence as to how close PPHM & Mem.Sloan/Wolchok have become than to look at AACR’17 (See http://tinyurl.com/zzldh9n ). The new (2nd) PPHM+MSK study revealed by the 3-1-17 abstracts is a complete mindblower (to me!):
#2. MSKCC+PPHM: 4-3-17 #1651, “PSTargeting+Adoptive TCell Transfer (ACT) Eliminates Adv. Tumors w/o Off-Target Toxicities, Melanoma” <=NEW(2nd) Joint MemSloan/PPHM study, see: http://tinyurl.com/h3ylrku
.
.
= = = = = = = = = = = = = = = = = = = =
Dr. Wolchok spoke about Bavi in the 11-14-16/PR (SITC’16, Joint MSKCC & PPHM Poster, “Phosphatidylserine Targeting Antibody in Combination with Checkpoint Blockade & Tumor Radiation Therapy Promotes Anti-Cancer Activity in Mouse Melanoma”)…
FULL SITC’16 ABSTRACT #199: http://bit.ly/2dHTEVn
11-14-16/JEDD WOLCHOK: "Based on these study results, we believe that the targeting of PS is having meaningful activity within the tumor microenvironment in the B16 melanoma model. It appears that this activity creates a more immune active environment in which other treatments, including radiation, are able to have a greater anti-tumor impact." http://tinyurl.com/js3fca4
11-14-16/TAHA MERGHOUB (Co-Dir., MSK’s Ludwig Collab. Lab): "We have noted that the combination of PS-targeting treatment and radiation, as well as triple combination of PS-targeting treatment, radiation and anti-PD-1, resulted in clear advantages in anti-tumor activity in the mouse B16 melanoma model. We believe that these findings suggest the potential benefit of combining these agents to improve the outcomes of patients with cancer. With this in mind, we think this research may play an important role in designing future clinical trials of PS-targeting agents in melanoma and other cancers." http://tinyurl.com/js3fca4
